Amphastar Pharmaceuticals (AMPH) vs Cronos Group (CRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cronos Group (CRON) has outperformed Amphastar Pharmaceuticals (AMPH) over the past year, gaining 23.7% versus a loss of 1.1%. Over five years, AMPH leads with a +33.6% price change compared with -40.9% for CRON. Cronos Group is the larger company by market cap ($1.19 billion vs $1.09 billion), about 1.1 times the size.
On valuation, Amphastar Pharmaceuticals trades at a lower trailing P/E (15.1x vs 17.1x for Cronos Group).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | CRON |
|---|---|---|
| Share price | $25.54 | $3.24 |
| Market cap | $1.09B | $1.19B |
| 1-day change | -1.43% | -1.37% |
| YTD return | -4.63% | +23.19% |
| 1-year return | -1.12% | +23.66% |
| 5-year return | +33.65% | -40.88% |
| P/E ratio (TTM) | 15.11 | 17.05 |
| Forward P/E | 8.03 | — |
| EPS (TTM) | $1.69 | $0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.52 | $3.61 |
| 52-week low | $16.65 | $2.28 |
| Distance from 52-week high | -13.48% | -10.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -11.90% | -24.07% |
| Average volume | 467.79K | 1.14M |
| Shares outstanding | 42.54M | 368.41M |
| Employees | 1,976 | 610 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRON has outperformed AMPH by 24.8 percentage points over the past year.
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Health Care · Medicinal Chemicals and Botanical Products · 610 employees
AMPH vs CRON FAQ
Which is bigger, Amphastar Pharmaceuticals or Cronos Group?
Cronos Group (CRON) is larger, with a market capitalization of $1.19B compared with $1.09B for Amphastar Pharmaceuticals (AMPH).
Which stock has performed better over the past year, AMPH or CRON?
CRON returned +23.66% over the past 12 months, compared with -1.12% for AMPH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMPH or CRON?
AMPH has the lower trailing P/E at 15.1, versus 17.1 for CRON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amphastar Pharmaceuticals and Cronos Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Amphastar Pharmaceuticals and Medicinal Chemicals and Botanical Products for Cronos Group.